Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Breo Ellipta Stumbles On Pediatric Asthma Claim, But Advair Helps Break The Fall

Executive Summary

FDA approves GlaxoSmithKline’s LABA/inhaled corticosteroid combo for asthma in adults but says more data needed in adolescents. GSK plans to throw additional promotional support behind the existing pediatric asthma claim for Advair, which is expected to face generic competition in the coming years.

You may also be interested in...



Asthma Trials May Need More Pediatric Focus After GSK’s Mepolizumab, Breo Ellipta Woes

Mepolizumab seems headed for approval in severe asthma – but only in adults; adolescent data in pivotal studies were promising, but too limited.

FDA Looks Likely To Split Decision On Mepolizumab Approval

An advisory committee was nearly unanimous that GSK’s clinical program demonstrated efficacy and safety for the IL-5 inhibitor in adult patients with severe asthma, but voted no on approval in patients ages 12-17.

GSK Plays Down Seretide/Advair Generic Launch In U.K., But Pressure Builds

Mylan’s launch in the U.K. of the first generic version of anti-asthma drug Seretide (Advair in the U.S.) has been a long-time coming -- and the copycat version has key differences from the original -- but the event underscores building pressures on GSK’s respiratory franchise.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS056852

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel